Numeric Investors LLC Takes Position in Horizon Pharma PLC (HZNP)

Numeric Investors LLC purchased a new position in Horizon Pharma PLC (NASDAQ:HZNP) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 30,900 shares of the biopharmaceutical company’s stock, valued at approximately $500,000.

Several other institutional investors have also modified their holdings of HZNP. Strs Ohio raised its position in shares of Horizon Pharma PLC by 3.8% in the third quarter. Strs Ohio now owns 21,800 shares of the biopharmaceutical company’s stock worth $395,000 after buying an additional 800 shares during the period. Envestnet Asset Management Inc. raised its position in shares of Horizon Pharma PLC by 0.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 120,714 shares of the biopharmaceutical company’s stock worth $1,954,000 after buying an additional 800 shares during the period. Boston Advisors LLC raised its position in shares of Horizon Pharma PLC by 7.3% in the third quarter. Boston Advisors LLC now owns 24,125 shares of the biopharmaceutical company’s stock worth $437,000 after buying an additional 1,640 shares during the period. California State Teachers Retirement System raised its position in shares of Horizon Pharma PLC by 0.9% in the third quarter. California State Teachers Retirement System now owns 341,833 shares of the biopharmaceutical company’s stock worth $6,197,000 after buying an additional 3,000 shares during the period. Finally, BlackRock Investment Management LLC raised its position in shares of Horizon Pharma PLC by 0.8% in the third quarter. BlackRock Investment Management LLC now owns 605,733 shares of the biopharmaceutical company’s stock worth $10,982,000 after buying an additional 4,953 shares during the period. Institutional investors own 88.09% of the company’s stock.

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Horizon Pharma PLC (NASDAQ:HZNP) opened at 15.13 on Monday. The stock’s 50 day moving average is $16.22 and its 200 day moving average is $17.60. The firm’s market cap is $2.46 billion. Horizon Pharma PLC has a one year low of $13.05 and a one year high of $23.44.

Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, February 27th. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the Zacks’ consensus estimate of $0.51 by $0.13. The firm had revenue of $310.30 million for the quarter, compared to analyst estimates of $307.93 million. Horizon Pharma PLC had a negative net margin of 1.34% and a positive return on equity of 22.73%. The business’s revenue for the quarter was up 26.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.63 EPS. On average, analysts predict that Horizon Pharma PLC will post $2.18 earnings per share for the current fiscal year.

Your IP Address:

A number of equities analysts have recently commented on the stock. Jefferies Group LLC set a $26.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Sunday, December 18th. Citigroup Inc upgraded shares of Horizon Pharma PLC from a “neutral” rating to a “buy” rating in a report on Monday, November 28th. Zacks Investment Research upgraded shares of Horizon Pharma PLC from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 13th. Mizuho lowered shares of Horizon Pharma PLC from a “buy” rating to a “neutral” rating and dropped their target price for the company from $30.00 to $14.00 in a report on Friday, December 9th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $24.00 target price (down previously from $29.00) on shares of Horizon Pharma PLC in a report on Thursday, December 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Horizon Pharma PLC presently has a consensus rating of “Buy” and a consensus price target of $28.23.

In related news, EVP Robert Carey sold 31,808 shares of the stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $16.03, for a total transaction of $509,882.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 2.10% of the stock is currently owned by company insiders.

Horizon Pharma PLC Company Profile

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

5 Day Chart for NASDAQ:HZNP

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/numeric-investors-llc-takes-position-in-horizon-pharma-plc-hznp/1708893.html

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *